PE-Cy7 Mouse Anti-Human HLA-DR Antibody (S-R566)

產(chǎn)品型號(hào)：S0B5516

更新時(shí)間：2025-06-30

廠商性質(zhì)：生產(chǎn)廠家

訪問(wèn)量：106

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

神經(jīng)纖維絲輕鏈(NfL)單抗：助力神經(jīng)損傷診斷

探索CD45在免疫治療中的潛力

HA標(biāo)簽重組兔單抗具有增強(qiáng)蛋白定位的能力

產(chǎn)品介紹

HLA-DR is a subtype of the human leukocyte antigen （HLA） complex, specifically classified as a class II molecule, and is encoded by genes located on chromosome 6. It plays a crucial role in the immune system by presenting peptide antigens to CD4+ T cells, which subsequently trigger adaptive immune responses, including the activation of B cells and the production of antibodies. HLA-DR is primarily expressed on antigen-presenting cells such as macrophages, dendritic cells, and B cells, and its expression levels can indicate the degree of immune system activation. This molecule is also significant in clinical settings, as it is associated with various autoimmune diseases （e.g., rheumatoid arthritis linked to HLA-DR4） and is a key factor in determining the success of organ transplants. Additionally, HLA-DR has been studied in the context of cancer immunotherapy, where its expression on tumor cells can influence the effectiveness of immune-mediated tumor suppression.

上一個(gè)：S0B5517PE-Cy7 Rat Anti-Mouse CD4 Antibody (S-R382)